Skip to main content
SpringerLink
Log in

Highlights ESMO 2021—lung cancer

  • review
  • Published:
memo - Magazine of European Medical Oncology Aims and scope Submit manuscript

Summary

The following three abstracts presented at EESMO 2021 highlight three different areas of therapeutic strategies for non small cell lung cancer. First, neoadjuvant Atezolizumab managed to show a superior DFS compared to best supportive care in completely resected NSCLC stage II–IIIA. Second, Cemiplimab combined with chemotherapy reached the primary endpoint of OS compared to chemo alone in advanced stage IIIB/C & stage IV NSCLC patients. Third, the BEVERLY trial showed that the combination of Erlotinib with Bevacizumab in advanced EGFR-mutated NSCLC prooved to be superior to Erlotinib monotherapy in the current/former smoker subgroup, suggesting that this subgroup represents a differnt tumor biology with sprecial therapeutic needs.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Felip E, et al. Sites of relapse and subsequent therapy from a phase III study of atezolizumab vs best supportive care after adjuvant chemotherapy in stage IB–IIIA NSCLC. In: Presidential symposium 3; September 20th, 2021. Presentation LBA9. Annals of Oncology 2021;32(suppl_5):S1283–346. https://doi.org/10.1016/annonc/annonc741.

    Article  Google Scholar 

  2. Felip E, et al. Adjuvant atezolizumab after adjuvant chemotherapy in resected stage IB–IIIA non-small-cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial. The Lancet 2021. https://doi.org/10.1016/S0140-6736(21)02098-5

    Article  PubMed  Google Scholar 

  3. Altorki N, Felip E, Zhou C, et al. IMpower010: characterization of stage IB–IIIA NSCLC patients by type and extent of therapy prior to adjuvant atezolizumab. In: International Association for the Study of Lung Cancer 2021 World Conference on Lung Cancer; September 8–14, 2021; virtual. Abstract PL02.05.

    Google Scholar 

  4. Zhou C, et al. IMpower010: biomarkers of disease-free survival (DFS) in a Phase 3 study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB–IIIA NSCLC. In: Proffered Paper session 1; 2O – IMpower010; December 9th, 2021. Annals of Oncology 2021;32(suppl_7):S1373–91. https://doi.org/10.1016/annonc/annonc784.

    Article  Google Scholar 

  5. Gogishvili M, et al. Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). In: Mini oral session – NSCLC, metastatic; September 19th, 2021. Presentation LBA51. Annals of Oncology 2021;32(suppl_5):S1283–346. https://doi.org/10.1016/annonc/annonc741.

    Article  Google Scholar 

  6. Gogishvili M, et al. Cemiplimab in combination with platinum doublet chemotherapy for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC). In: Mini oral session – NSCLC, metastatic; September 19th, 2021. Presentation LBA51. Annals of Oncology 2021;32(suppl_5):S1283–346. https://doi.org/10.1016/annonc/annonc741.

    Article  Google Scholar 

  7. Piccirillo MC. Bevacizumab + erlotinib vs erlotinib alone as first-line treatment of pts with EGFR mutated advanced non squamous NSCLC: Final analysis of the multicenter, randomized, phase III BEVERLY trial. In: Proffered Paper session – NSCLC, metastatic 1; September 18th, 2020. Presentation 12070. Annals of Oncology 2021;32(suppl_5):S949–1039. https://doi.org/10.1016/annonc/annonc729.

    Article  Google Scholar 

  8. Saito H, et al. Erlotinib plus bevacizumab versus erlotinib alone in patients with EGFR-positive advanced non-squamous non-small-cell lung cancer (NEJ026): interim analysis of an open-label, randomised, multicentre, phase 3 trial. LancetOncolol. 2019;20(5):625–35.

    CAS  Google Scholar 

  9. Maemondo M, et al. NEJ026: Final overall survival analysis of bevacizumab plus erlotinib treatment for NSCLC patients harboring activating EGFR-mutations. JCO Clin Cancer Inform. 2020;38(15suppl):9506.

    Google Scholar 

  10. Soo R. A randomized phase II study of second-line osimertinib (Osi) and bevacizumab (Bev) versus Osi in advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) and T790M mutations (mt): Results from the ETOP BOOSTER trial. In: Virtual Plenary Debate; September 17th, 2021; Abstract VP3_2021.

    Google Scholar 

  11. Kenmotsu H, et al. Primary results of a randomized phase II study of osimertinib plus bevacizumab versus osimertinib monotherapy for untreated patients with non-squamous non-small cell lung cancer harboring EGFR mutations: WJOG9717L study. In: Proffered Paper session – NSCLC, metastatic; September 18th, 2021. Presentation LBA44. Annals of Oncology 2021;32(suppl_5):S1283–346. https://doi.org/10.1016/annonc/annonc741.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pulmonology, Klinikum Klagenfurt am Wörthersee, Feschnigstraße 11, 9020, Klagenfurt, Austria

    Markus Rauter

Authors
  1. Markus Rauter
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Markus Rauter.

Ethics declarations

Conflict of interest

M. Rauter declares that he has no competing interests.

Additional information

Publisher’s Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Rauter, M. Highlights ESMO 2021—lung cancer. memo 15, 107–110 (2022). https://doi.org/10.1007/s12254-022-00801-0

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12254-022-00801-0

Keywords

Search

Navigation